articleThe LancetApr 17, 2015Closed access

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

University of North Carolina at Chapel Hill · Columbia University · +11 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

597
total citations
FWCI
56.66
Percentile
100%
References
32
Citations per year

Authors

24

Topics & keywords

Keywords
  • Cobicistat
  • Elvitegravir
  • Tenofovir alafenamide
  • Emtricitabine
  • Medicine
  • Human immunodeficiency virus (HIV)
  • Double blind
  • Virology
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.